Research programme: focal adhesion kinase inhibitors - Novartis

Drug Profile

Research programme: focal adhesion kinase inhibitors - Novartis

Alternative Names: NVP-TAE 226; TAE 226

Latest Information Update: 22 May 2012

Price : $50

At a glance

  • Originator Novartis
  • Class Benzamides; Pyrimidines; Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 22 May 2012 No development reported - Preclinical for Cancer in Japan (PO)
  • 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
  • 24 Oct 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top